课题基金 / 基金详情

Washington University Center for Translational Neuroscience

Washington University Center for Translational Neuroscience
华盛顿大学转化神经科学中心
批准号:
7663813
负责人:
DAVID M. HOLTZMAN
金额:
$163.96万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-25 至 2011-08-31

项目摘要

项目成果

DAVID M. HOLTZMAN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):这项名为“华盛顿大学转化神经科学中心- WUCTN”的拨款的总体目标是支持华盛顿大学神经科学研究人员共享的集中资源、设施和专业知识,以促进发现神经系统疾病的基本机制,并将这种理解转化为治疗和治愈。核心A,行政管理,将组织和促进其他6个核心之间的互动:核心B,生物标本和临床数据采集;核心C,分子分析;核心D,病毒载体;Core E,光学成像;核心F,功能评估;核心G是信息学。通过汇集和组织资源和专业知识,华盛顿大学神经科学社区的巨大广度和合作精神几乎跨越了每个部门,可以利用规模经济,面对个人研究人员无法应对的挑战,并开发一个基础设施,为120多名研究人员的用户群体服务。WUCTN将利用华盛顿大学3个新项目的发展和资源:生物医学21、神经疾病希望中心和神经临床研究部门,并利用建立已久的麦克唐纳神经科学中心的支持和专业知识,协助支持本提案所要求的人员和基础设施。此外,我们将与华盛顿大学的几个正在进行的NIH资助的中心合作,包括阿尔茨海默病研究中心,精神分裂症神经生物学研究Conte中心和NINDS脑成像中心核心,为该提案增加“额外价值”。描述生物现象所需的技术的复杂性和成本日益增加,往往超出了单个实验室的专业知识和资源。如果没有专门从事这些技术的设施,就很难以一致、及时、经济的方式建立和验证关键的新发现。拟议的核心基础设施位于华盛顿大学基础神经科学和疾病社区神经生物学之间的协作环境中,将有助于催化强有力的转化努力,将基础发现转化为诊断和治疗进展。这将表现为:1)个别调查人员更有效地利用使能技术;2)在潜在治疗策略的临床前开发方面加强合作;3)更快地将最初的发现转化为治疗神经系统疾病的有效方法。与公共卫生相关:这项核心拨款将建立技术资源和技术专长,以促进与神经和精神疾病相关的基础神经科学发现转化为新的诊断和治疗机会。
英文摘要
DESCRIPTION (provided by applicant): The overarching goal of this grant, entitled "Washington University Center for Translational Neuroscience- WUCTN" is to support centralized resources, facilities, and expertise shared by neuroscience investigators at Washington University in order to facilitate discovery of fundamental mechanisms of disorders of the nervous system and to translate this understanding into treatments and cures. Core A, Administration, will organize and facilitate interaction among the 6 other cores: Core B, Biospecimen and Clinical Data Acquisition; Core C, Molecular Analysis; Core D, Viral Vectors; Core E, Optical imaging; Core F, Functional Assessment; and Core G, Informatics. By pooling and organizing resources and expertise, the enormous breadth and collaborative spirit of the Washington University neuroscience community that spans virtually every department, can take advantage of economies of scale, confront challenges too large for individual investigators, and develop an infrastructure that will serve the user group of over 120 investigators. The WUCTN will capitalize on the development and resources of 3 new initiatives at Washington University: Biomed 21, the Hope Center for Neurological Disorders, and the Neurological Clinical Research Unit as well as utilize the support and expertise of the long established McDonnell Neuroscience Centers to assist in supporting the personnel and infrastructure being requested in this proposal. In addition, we will work together with several ongoing NIH funded centers at Washington University including the Alzheimer's Disease Research Center, the Conte Center for research on the neurobiology of schizophrenia, and the NINDS Center Core for Brain Imaging to add "extra value" to this proposal. The increasing complexity and cost of the technologies required to characterize biological phenomenon are often beyond the expertise and resources of an individual laboratory. This makes it very difficult to establish and validate key new discoveries in a cohesive, timely, and cost-efficient manner without access to facilities specializing in these enabling technologies. The proposed Core infrastructure, situated within the collaborative environment that exists between the basic neurosciences and the neurobiology of disease community at Washington University, will help catalyze a strong translational effort to convert basic discoveries into diagnostic and therapeutic advances. This will be manifested as: 1) greater efficiency in utilizing enabling technologies by individual investigators; 2) greater collaboration aimed at pre-clinical development of potential therapeutic strategies; and, 3) faster translation of initial discoveries into useful treatments for disorders of the nervous system. Relevance to public health: This Core grant will establish enabling technology resources and technical expertise to facilitate the transition of basic neuroscience discoveries relevant to neurologic and psychiatric diseases into novel diagnostic and therapeutic opportunities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cerebral amyloid angiopathy: Role of ApoE, innate immunity, and meningeal lymphatics
  • 批准号:
    10674679
  • 项目类别:
  • 资助金额:
    $62.0万
  • 财政年份:
    2022
  • 负责人:
    DAVID M. HOLTZMAN
  • 依托单位:
APOE effects on glial lipid metabolism and 25-hydroxycholesterol: Effects on aging and AD-related pathology
  • 批准号:
    10667466
  • 项目类别:
  • 资助金额:
    $53.02万
  • 财政年份:
    2021
  • 负责人:
    DAVID M. HOLTZMAN
  • 依托单位:
APOE effects on glial lipid metabolism and 25-hydroxycholesterol: Effects on aging and AD-related pathology
  • 批准号:
    10407944
  • 项目类别:
  • 资助金额:
    $54.01万
  • 财政年份:
    2021
  • 负责人:
    DAVID M. HOLTZMAN
  • 依托单位:
Administration Core
  • 批准号:
    10622634
  • 项目类别:
  • 资助金额:
    $80.27万
  • 财政年份:
    2020
  • 负责人:
    DAVID M. HOLTZMAN
  • 依托单位:
海外基金